The global nanomedicine
market is anticipated to reach USD 350.8 billion by 2025,
according to a new report by Grand View Research, Inc. Development of novel
nanotechnology-based drugs and therapies is driven by the need to develop
therapies that have fewer side effects and that are more cost-effective than
traditional therapies, in particular for cancer.
Application of nanotechnology-based contrast reagents
for diagnosis and monitoring of the effects of drugs on an unprecedented short
timescale is also attributive drive growth in the coming years. Additionally,
demand for biodegradable implants with longer lifetimes that enable tissue
restoration is anticipated to influence demand.
As per the WHO factsheet, cancer is found to be one of
the major causes of mortality and morbidity worldwide, with approximately 14
million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand
for nanomedicine in order to curb such high incidence rate is expected to boost
market progress during the forecast period.
Solutions such as nanoformulations with triggered
release for tailor-made pharmacokinetics, nanoparticles for local control of
tumor in combination with radiotherapy, and functionalized nanoparticles for
targeted in-vivo activation of stem cell production are anticipated to drive R&D,
consequently resulting in revenue generation in the coming years.
Biopharmaceutical and medical devices companies are
actively engaged in development of novel products as demonstrated by the
increasingly growing partnerships between leading enterprises and nanomedicine
startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a
global collaboration and a licensing agreement for development and discovery of
innovative drugs with multi-specific nanobodies. This strategic partnership is
anticipated to rise the net annual sales of the products uplifting the market
growth.
However, in contrary with the applications of
nanotechnology, the entire process of lab to market approval is a tedious and
expensive one with stringent regulatory evaluation involved thereby leading
investors to remain hesitant for investments.
Browse full research report on Nanomedicine Market: https://www.grandviewresearch.com/industry-analysis/nanomedicine-market
Further key findings from the report suggest:
- Therapeutics accounted for the largest share of market revenue in
2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices
- These devices possess the ability to cross biological barriers.
Moreover, presence of drugs such as Doxil, Abraxane, and Emend is
attributive for higher revenue generation
- Presence of substantial number of products manufactured through the
use of microbial sources can be attributed for the largest share
- In-vitro diagnostics is expected to witness lucrative progress as a
result of R&D carried out in this segment
- Introduction of nano-enabled biomarkers, vectors and contrast
agents with high-specificity and sensitivity are attributive for projected
progress
- Clinical cardiology is expected to witness the fastest growth
through to 2025 owing to development in nano-functionalization and
modification of surfaces for increased biocompatibility of implants in
treatment of late thrombosis
- Moreover, an abundance of research publications and patent filings
from European region with a share of about 25% in nanomedicine-related
publications is supportive for revenue generation from European economies
- Asia Pacific is estimated to witness the fastest growth over the
forecast period
- Factors responsible include government and regulatory authorities
that have implemented a framework to encourage R&D collaborations and
framework extension.
- Key players operating in this industry include Pfizer Inc., Ablynx
NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead
Research Inc., Celgene Corporation, Bio-Gate AG, and Merck
- Active expansion strategies are undertaken by a number of the major
market entities in order to strengthen their position
- North America dominated the industry in 2016, accounting for a 42%
of total revenue
- Presence of key participants operating in the region are involved
in collaborative activities are attributive for the largest share of North
America in sector revenue
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand
View Research has segmented the nanomedicine market on the basis of product,
application, nanomolecule type, and region:
Nanomedicine
Product Outlook (Revenue, USD Billion; 2013 - 2025)
- Therapeutics
- Regenerative
medicine
- In-vitro
diagnostics
- In-vivo
diagnostics
- Vaccines
Nanomedicine
Application Outlook (Revenue, USD Billion; 2013 - 2025)
- Clinical
Oncology
- Infectious
diseases
- Clinical
Cardiology
- Orthopedics
- Others
Nanomedicine
Nanomolecule Type Outlook (Revenue, USD Billion; 2013 - 2025)
- Nanoparticles
- Metal &
Metal Oxide Nanoparticles
- By Type
- Gold
Nanoparticles
- Silver
Nanoparticles
- Iron Oxide
Nanoparticles
- Alumina
Nanoparticles
- Gadolinium
Oxide Nanoparticles
- Others
- By
Application
- In-vivo Imaging
- Targeted
Drug Delivery
- Proton
Therapy
- In-vitro
assays
- Cell &
Phantom Imaging
- Liposomes
- Polymers
& polymer drug conjugates
- Hydrogel
nanoparticles
- Dendrimers
- Inorganic
nanoparticles
- Nanoshells
- Nanotubes
- Nanodevices
Nanomedicine
Regional Outlook (Revenue, USD Billion; 2013 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East
and Africa (MEA)
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment